Hidradenitis Suppurativa Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corp, CSL

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hidradenitis Suppurativa pipeline constitutes 24+ key companies continuously working towards developing 24+ Hidradenitis Suppurativa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hidradenitis Suppurativa Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hidradenitis Suppurativa Market.

The Hidradenitis Suppurativa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Hidradenitis Suppurativa Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight [https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key takeaways from the Hidradenitis Suppurativa Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Hidradenitis Suppurativa treatment therapies with a considerable amount of success over the years.

*
Hidradenitis Suppurativa companies working in the treatment market are InflaRx, AnaptysBio, Kymera Therapeutics, CSL Behring, Azora Therapeutics, Union Therapeutics, Eli Lilly and company, Boehringer Ingelheim, ACELYRIN, Incyte Corporation, InflaRx, Novartis, ChemoCentryx, Janssen Pharmaceutical/XBiotech, Aclaris Therapeutics, and others, are developing therapies for the Hidradenitis Suppurativa treatment

*
Emerging Hidradenitis Suppurativa therapies in the different phases of clinical trials are- Vilobelimab, Imsidolimab, KT-474, CSL324, AT193, Orismilast, LY3041658, Spesolimab, Izokibep, INCB054707, IFX-1, Cosentyx/Secukinumab, Avacopan, Bermekimab, Zunsemetinib (ATI-450), and others are expected to have a significant impact on the Hidradenitis Suppurativa market in the coming years.

*
In March 2026, Global pharmaceutical leader Novartis has revealed that its drug Cosentyx (secukinumab) has gained FDA approval for use in pediatric patients aged 12 years and above with moderate to severe hidradenitis suppurativa (HS). This makes it the only IL-17A inhibitor authorized for this age group. The approval introduces a valuable biologic therapy option, enabling more personalized treatment approaches and strengthening Cosentyx's role in the hidradenitis suppurativa treatment landscape.

*
In March 2026, Incyte's dermatology drug demonstrated sustained symptom improvement in late-stage clinical trials. The company evaluated povorcitinib in patients with moderate to severe hidradenitis suppurativa, a chronic skin condition characterized by painful nodules, abscesses, and scarring, typically occurring in areas where skin rubs together, such as the underarms or groin.

*
In September 2025, New late-breaking data indicate that povorcitinib therapy significantly improves moderate to severe hidradenitis suppurativa (HS) through Week 24. These interim 24-week results come from the pivotal Phase 3 STOP-HS trial, which evaluated povorcitinib (INCB54707), a highly selective oral JAK1 inhibitor, in adults aged 18 and older. The findings were presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress held in Paris, France.

*
In September 2025, UCB, a global biopharmaceutical company, has shared three-year results from the BE HEARD trials evaluating BIMZELX Registered (bimekizumab-bkzx) in adults with moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only approved therapy to selectively target both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), remained generally well tolerated and continued to provide sustained symptom relief over the study period.

*
In March 2025, Incyte (Nasdaq: INCY) has reported promising topline results from its pivotal Phase 3 STOP-HS clinical program, which evaluated the safety and efficacy of povorcitinib (INCB054707) an oral small-molecule JAK1 inhibitor-in adults aged 18 and above with moderate to severe hidradenitis suppurativa (HS). Both the STOP-HS1 and STOP-HS2 studies met their primary endpoints for the two tested doses (45 mg and 75 mg).

*
In March 2025, UCB, a global biopharmaceutical company, has released two-year data from the BE HEARD^ trials assessing BIMZELX Registered (bimekizumab-bkzx) for treating moderate-to-severe hidradenitis suppurativa (HS). BIMZELX is the first and only approved therapy that specifically targets both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). The findings highlight the drug's continued effectiveness in delivering lasting symptom relief and consistent disease management, with promising potential to reduce the risk of long-term structural damage caused by draining tunnels (DTs).

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa is a chronic skin condition characterized by painful, inflamed lumps, abscesses, and scarring, usually occurring in areas with sweat glands like the armpits, groin, and under the breasts. It results from blocked hair follicles and causes recurrent flare-ups, leading to discomfort and potential infection. The exact cause is unclear, but it is linked to inflammation and sometimes genetic factors.

Explore the latest Hidradenitis Suppurativa pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Hidradenitis Suppurativa Clinical Trials [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Hidradenitis Suppurativa Drugs Under Different Phases of Clinical Development Include:

*
Vilobelimab: InflaRx

*
Imsidolimab: AnaptysBio

*
KT-474: Kymera Therapeutics

*
CSL324: CSL Behring

*
AT193: Azora Therapeutics

*
Orismilast: Union Therapeutics

*
LY3041658: Eli Lilly and company

*
Spesolimab: Boehringer Ingelheim

*
Izokibep: ACELYRIN

*
INCB054707: Incyte Corporation

*
IFX-1: InflaRx

*
Cosentyx/Secukinumab: Novartis

*
Avacopan: ChemoCentryx

*
Bermekimab: Janssen Pharmaceutical/XBiotech

*
Zunsemetinib (ATI-450): Aclaris Therapeutics

Hidradenitis Suppurativa Route of Administration

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Hidradenitis Suppurativa Molecule Type

Hidradenitis Suppurativa Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Hidradenitis Suppurativa Pipeline Therapeutics Assessment

*
Hidradenitis Suppurativa Assessment by Product Type

*
Hidradenitis Suppurativa By Stage and Product Type

*
Hidradenitis Suppurativa Assessment by Route of Administration

*
Hidradenitis Suppurativa By Stage and Route of Administration

*
Hidradenitis Suppurativa Assessment by Molecule Type

*
Hidradenitis Suppurativa by Stage and Molecule Type

DelveInsight's Hidradenitis Suppurativa Report covers around 24+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Hidradenitis Suppurativa product details are provided in the report. Download the Hidradenitis Suppurativa pipeline report to learn more about the emerging Hidradenitis Suppurativa therapies [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Hidradenitis Suppurativa Therapeutics Market include:

Key companies developing therapies for Hidradenitis Suppurativa are - I nf laRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, Kymera Therapeutics, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics, and others.

Hidradenitis Suppurativa Pipeline Analysis:

The Hidradenitis Suppurativa pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Hidradenitis Suppurativa with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa Treatment.

*
Hidradenitis Suppurativa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Hidradenitis Suppurativa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hidradenitis Suppurativa market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hidradenitis Suppurativa drugs and therapies [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hidradenitis Suppurativa Pipeline Market Drivers

*
Increase in the incidence of chronic inflammatory skin diseases, large number of ongoing clinical trials, increasing knowledge about skin diseases are some of the important factors that are fueling the Hidradenitis Suppurativa Market.

Hidradenitis Suppurativa Pipeline Market Barriers

*
However, high cost of therapy, side-effects associated and other factors are creating obstacles in the Hidradenitis Suppurativa Market growth.

Scope of Hidradenitis Suppurativa Pipeline Drug Insight

*
Coverage: Global

*
Key Hidradenitis Suppurativa Companies: InflaRx, AnaptysBio, Kymera Therapeutics, CSL Behring, Azora Therapeutics, Union Therapeutics, Eli Lilly and company, Boehringer Ingelheim, ACELYRIN, Incyte Corporation, InflaRx, Novartis, ChemoCentryx, Janssen Pharmaceutical/XBiotech, Aclaris Therapeutics, and others

*
Key Hidradenitis Suppurativa Therapies: Vilobelimab, Imsidolimab, KT-474, CSL324, AT193, Orismilast, LY3041658, Spesolimab, Izokibep, INCB054707, IFX-1, Cosentyx/Secukinumab, Avacopan, Bermekimab, Zunsemetinib (ATI-450), and others

*
Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa current marketed and Hidradenitis Suppurativa emerging therapies

*
Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and Hidradenitis Suppurativa market barriers

Request for Sample PDF Report for Hidradenitis Suppurativa Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hidradenitis Suppurativa Report Introduction

2. Hidradenitis Suppurativa Executive Summary

3. Hidradenitis Suppurativa Overview

4. Hidradenitis Suppurativa- Analytical Perspective In-depth Commercial Assessment

5. Hidradenitis Suppurativa Pipeline Therapeutics

6. Hidradenitis Suppurativa Late Stage Products (Phase II/III)

7. Hidradenitis Suppurativa Mid Stage Products (Phase II)

8. Hidradenitis Suppurativa Early Stage Products (Phase I)

9. Hidradenitis Suppurativa Preclinical Stage Products

10. Hidradenitis Suppurativa Therapeutics Assessment

11. Hidradenitis Suppurativa Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hidradenitis Suppurativa Key Companies

14. Hidradenitis Suppurativa Key Products

15. Hidradenitis Suppurativa Unmet Needs

16 . Hidradenitis Suppurativa Market Drivers and Barriers

17. Hidradenitis Suppurativa Future Perspectives and Conclusion

18. Hidradenitis Suppurativa Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hidradenitis-suppurativa-pipeline-2026-moa-and-roa-insights-clinical-trials-status-and-key-companies-involved-by-delveinsight-inflarx-novartis-ucb-abbvie-pfizer-amgen-incyte-corp-csl]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.